Physician profile
Patrick Burchell
NPI 1841649357
$2,696.81
in general payments reported to CMS, 2019-2025
15 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $121 · 2021: $171 · 2022: $212 · 2023: $552 · 2024: $520 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,011.13 | 2020-2023 | Tepezza |
| Amgen INC. | $632.55 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $477.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $151.82 | 2019-2024 | Eylea Hd |
| Kala Pharmaceuticals, INC. | $119.70 | 2019 | |
| Allergan, INC. | $107.60 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $47.96 | 2024-2025 | Xdemvy |
| Incyte Corporation | $29.61 | 2023 | Opzelura |
| Ani Pharmaceuticals, INC. | $20.62 | 2024 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $20.09 | 2024 | Syfovre |
| Bausch & Lomb Americas INC. | $19.55 | 2025 | Xipere |
| Galderma Laboratories, L.P. | $15.17 | 2024 | Dysport |
| Halozyme INC | $15.08 | 2025 | Hylenex Recombinant |
| Abbvie INC. | $14.86 | 2023 | Vuity, Alphagan P, Lumigan |
| Biotissue Holdings INC. | $13.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Burchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.